IRVINE, Calif.--(BUSINESS WIRE)--In response to public reports suggesting a causal link between a BOTOX® Cosmetic treatment in 2003 and a fatality, Allergan, Inc. (NYSE:AGN) today provided further assurance to patients and the public about BOTOX® Cosmetic and BOTOX® (Botulinum Toxin Type A).
